← Russell 3000 cross-section

PLSE PULSE BIOSCIENCES, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$3.5bn
Revenue TTM
$1m
Net income TTM
$-80m
Free cash flow
$-61m
Composite score
Sector rank
#1307

Valuation

P / E
EV / EBITDA
EV / sales
2,858.9
FCF yield
-1.76%
Earnings yield vs 10-yr
-7.03pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-6,755.8%
EBITDA margin
-6,920.5%
ROE
-80.5%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$0.10m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In developing this guidance, the Company’s management must make certain assumptions and judgments about its future operating performance, including but not limited to projected hiring of sales and marketing professionals, growth of revenue in the relevant device markets, increase or decrease of its market share, costs of production of its recently introduced products, and stability of the macro-economic environment in the Company’s key markets.PULSE BIOSCIENCES, INC., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →